Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fludrocortisone acetate
Drug ID BADD_D00918
Description Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.[A5423]
Indications and Usage For partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
Marketing Status Prescription; Discontinued
ATC Code H02AA02
DrugBank ID DB00687
KEGG ID D00986
MeSH ID C034635
PubChem ID 225609
TTD Drug ID Not Available
NDC Product Code 69238-7033; 68084-288; 58159-074; 0115-7033; 55154-6645; 42291-764; 49452-3155; 51927-2408; 50268-330; 63629-8806; 71335-0976; 63629-7780; 14096-127; 42291-529; 46439-8721; 0615-6562; 38779-0129; 65089-0015; 62991-2773; 0555-0997
Synonyms fludrocortisone acetate | fluorocortisol acetate | fludrocortisone 21-acetate | 9 alpha-fluorocortisol acetate | Florinef | Cortineff
Chemical Information
Molecular Formula C23H31FO6
CAS Registry Number 514-36-3
SMILES CC(=O)OCC(=O)C1(CCC2C1(CC(C3(C2CCC4=CC(=O)CCC43C)F)O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Alkalosis hypokalaemic14.01.02.002--Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Benign intracranial hypertension17.07.02.001--Not Available
Blood potassium decreased13.11.01.010--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cardiomegaly02.04.02.001--Not Available
Cataract subcapsular06.06.01.002--Not Available
Cushingoid05.01.01.002; 24.08.02.004; 19.07.03.001; 14.11.01.006--
Dermatitis acneiform23.02.01.004--
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Erythema23.03.06.001--Not Available
Exophthalmos05.02.02.002; 06.09.04.001--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Glaucoma06.03.01.002--
Glucose tolerance impaired14.06.02.001; 05.06.02.001--
Glycosuria20.02.01.005--
Haemoglobin13.01.05.018--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hirsutism23.02.04.001; 05.05.01.005--
Hyperchlorhydria07.11.03.001--Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
The 1th Page    1 2 3    Next   Last    Total 3 Pages